HC Wainwright & Co. Reiterates Buy on Pacira BioSciences, Maintains $38 Price Target
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsReiterationPrice Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Pacira BioSciences (NASDAQ:PCRX) with a Buy and maintains $38 price target.
HC Wainwright & Co. analyst Douglas Tsao reiterates Pacira BioSciences (NASDAQ:PCRX) with a Buy and maintains $38 price target.